About P2Y purinoceptor 2
P2Y purinoceptor 2 (P2RY2) is a protein
from Homo sapiens identified by UniProt accession
P41231, 377 residues long.
MolForge cross-references it against 0 known binders and
244 disease associations.
Target properties
| Protein name | P2Y purinoceptor 2 |
| UniProt accession | P41231 |
| Gene | P2RY2 |
| Organism | Homo sapiens |
| Length | 377 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (4)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (244)
Diseases linked to this target (Open Targets).
- dry eye syndrome · score 0.56
- basophil count · score 0.53
- basophil percentage of leukocytes · score 0.50
- monocyte count · score 0.50
- platelet component distribution width · score 0.48
- blood protein measurement · score 0.47
- serum alanine aminotransferase measurement · score 0.46
- aspartate aminotransferase measurement · score 0.44
- platelet crit · score 0.43
- reticulocyte count · score 0.42
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P41231-F1 | alphafold | PREDICTED | 78.86 | — |
Amino-acid sequence (377 residues)
MAADLGPWND TINGTWDGDE LGYRCRFNED FKYVLLPVSY GVVCVPGLCL NAVALYIFLC RLKTWNASTT YMFHLAVSDA LYAASLPLLV YYYARGDHWP FSTVLCKLVR FLFYTNLYCS ILFLTCISVH RCLGVLRPLR SLRWGRARYA RRVAGAVWVL VLACQAPVLY FVTTSARGGR VTCHDTSAPE LFSRFVAYSS VMLGLLFAVP FAVILVCYVL MARRLLKPAY GTSGGLPRAK RKSVRTIAVV LAVFALCFLP FHVTRTLYYS FRSLDLSCHT LNAINMAYKV TRPLASANSC LDPVLYFLAG QRLVRFARDA KPPTGPSPAT PARRRLGLRR SDRTDMQRIE DVLGSSEDSR RTESTPAGSE NTKDIRL
Explore P2Y purinoceptor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets